What are the indications, dosing regimen, and precautions for using a potassium‑competitive acid blocker (e.g., vonoprazan)?

Potassium-Competitive Acid Blockers (P-CABs): Clinical Guide

P-CABs, particularly vonoprazan, are a newer class of acid-suppressing medications that should be used selectively rather than as first-line therapy for most acid-related conditions, with the notable exception of H. pylori eradication where they should replace PPIs. 1

Key Pharmacologic Advantages Over PPIs

P-CABs offer several mechanistic benefits that translate to superior acid suppression:

• Rapid onset: Achieve target pH within 4 hours (vs 3-5 days for PPIs) 2, 3
• Longer half-life: 5-9 hours allowing sustained acid control over 24 hours 3
• No meal timing required: Can be taken with or without food 2
• Minimal CYP2C19 variability: Genetic polymorphisms affect exposure by only 15-29%, clinically insignificant 3
• Reversible binding: Ionic rather than covalent binding to H+/K+-ATPase 1

Primary Indications and Dosing

H. pylori Eradication (PREFERRED OVER PPIs)

Use P-CABs instead of PPIs for most patients with H. pylori infection 1

Dosing regimens:

• Triple therapy: Vonoprazan 20 mg twice daily + amoxicillin + clarithromycin for 14 days 2
• Dual therapy: Vonoprazan 20 mg twice daily + amoxicillin for 14 days 2

Evidence supporting this recommendation:

• Eradication rates: 92% with vonoprazan vs 80% with PPIs in pooled Asian trials 1
• Clarithromycin-resistant strains: 66-70% eradication with vonoprazan vs 32% with PPIs 1
• Maastricht VI/Florence Consensus: 100% expert agreement that P-CABs are superior 1

Renal adjustments for H. pylori treatment:

• eGFR ≥30: 20 mg twice daily
• eGFR <30: Not recommended 2

Hepatic adjustments:

• Child-Pugh A: 20 mg twice daily
• Child-Pugh B or C: Not recommended 2

Severe Erosive Esophagitis (LA Grade C/D)

May use P-CABs for healing and maintenance, but cost considerations limit routine first-line use 1

Healing regimen:

• Vonoprazan 20 mg once daily for 8 weeks 2

Maintenance regimen:

• Vonoprazan 10-20 mg once daily for up to 6 months 2

Supporting evidence:

• Maintenance healing rates: 75-77% with vonoprazan vs 62% with lansoprazole 15 mg 1
• Recurrence rates: 5-13% with vonoprazan vs 39% with lansoprazole 1

When to use:

• PPI failures with confirmed GERD (LA grade B or greater, Barrett's esophagus, peptic stricture, or acid exposure time >6% on pH monitoring) 1
• Not justified as first-line given markedly higher costs and lack of comparison with double-dose PPIs 1

Renal adjustments for healing EE:

• eGFR ≥30: 20 mg once daily
• eGFR <30: 10 mg once daily 2

Hepatic adjustments:

• Child-Pugh A: 20 mg once daily
• Child-Pugh B or C: 10 mg once daily 2

Mild Erosive Esophagitis (LA Grade A/B)

Do not use as first-line therapy 1

• Healing rates similar to PPIs (94% vonoprazan vs 91% lansoprazole) 1
• Consider only after twice-daily PPI failure with confirmed acid-related reflux 1

Non-Erosive Reflux Disease (NERD)

Do not use as first-line therapy 1

Dosing if used:

• Vonoprazan 10 mg once daily for 4 weeks 2

Rationale:

• Limited evidence of superiority over PPIs
• Higher cost not justified
• Reserve for documented acid-related reflux failing twice-daily PPIs 1

Peptic Ulcer Disease

Do not use as first-line therapy for treatment or prophylaxis 1

Evidence:

• Noninferiority to PPIs demonstrated (94-96% healing rates for both) 1
• Higher costs without superior outcomes
• Exception: Consider for PPI treatment failures (excluding ulcers from cancer, infections, vasculitis, ischemia) 1

Potential role in ulcer bleeding:

• Emerging data shows noninferiority for high-risk stigmata ulcer bleeding (7.1% rebleeding with vonoprazan vs 10.4% with high-dose PPI) 1
• Currently insufficient evidence for first-line recommendation 1

Important Precautions and Monitoring

Contraindications

• Known hypersensitivity to vonoprazan (anaphylactic shock reported) 2
• Concurrent rilpivirine-containing products 2

Warnings

Gastric malignancy: Symptomatic response does not exclude cancer; consider endoscopy in older patients or those with suboptimal response 2

Acute tubulointerstitial nephritis: Discontinue if suspected 2

Clostridioides difficile risk: Use shortest duration appropriate 2

Bone fracture risk: Increased with high-dose, long-term use; manage osteoporosis risk per guidelines 2

Vitamin B12 deficiency: Long-term acid suppression can cause malabsorption; monitor if clinical symptoms develop 2

Hypomagnesemia: May lead to hypocalcemia/hypokalemia; monitor in at-risk patients or with concurrent digoxin use 2

Serum gastrin elevation: Mean levels higher than with PPIs but normalize within 4 weeks of discontinuation 3, 4

• Stop vonoprazan at least 4 weeks before measuring chromogranin A levels 2

Fundic gland polyps: Risk increases with long-term use 2

Drug Interactions

Significant interaction with clarithromycin: Mutual metabolic inhibition increases vonoprazan AUC by 1.8-fold and clarithromycin by 1.5-fold 3

CYP metabolism: Primarily CYP3A4, with contributions from CYP2B6, CYP2C19, CYP2D6, and SULT2A1 3

Administration Pearls

• Swallow whole: Do not chew or crush 2
• Timing flexibility: No meal restrictions 2
• Missed doses for GERD: Take within 12 hours; otherwise skip 2
• Missed doses for H. pylori: Take within 4 hours; otherwise skip and continue schedule 2

Cost-Effectiveness Considerations

The markedly higher cost of vonoprazan in the United States limits its routine use 1. Even modest clinical superiority over double-dose PPIs may not justify the cost differential for most indications. The short-term duration of H. pylori regimens reduces cost concerns in that specific setting 1.

Common Adverse Events

Most frequent (≥2%): 2, 4

• Gastritis, diarrhea, abdominal pain/distension, nausea (healing EE)
• Dysgeusia, headache, nasopharyngitis, urinary tract infection
• Nasopharyngitis was the only AE in ≥5% of patients (6.94% vonoprazan vs 5.07% PPI)

Safety profile comparable to PPIs with no unexpected signals in integrated analysis of 5,318 patients 4